Gelber R H, Murray L P, Siu P, Tsang M, Rea T H
San Francisco Regional Hansen's Disease Program, CA 94115.
Int J Lepr Other Mycobact Dis. 1994 Dec;62(4):568-73.
A clinical trial of minocycline in a total of 10 patients with previously untreated lepromatous leprosy was conducted in order to evaluate the efficacy of a single, initial, 200-mg dose and 100 mg twice daily of minocycline for a total duration of up to 3 months. Patients improved remarkably quickly. Although single-dose therapy did not result in a significant killing of Mycobacterium leprae, viable M. leprae were cleared from the dermis regularly by 3 months of twice-daily therapy, a rate similar to that achieved by minocycline 100 mg once daily. Because more side effects were noted herein than previously with 100 mg daily, we recommend that minocycline, when applied, be administered at 100 mg daily to leprosy patients.
为了评估米诺环素单次初始剂量200毫克以及每日两次每次100毫克、持续长达3个月的治疗效果,对总共10例未经治疗的瘤型麻风患者进行了一项米诺环素临床试验。患者改善得非常迅速。虽然单剂量疗法并未显著杀灭麻风分枝杆菌,但通过每日两次治疗3个月,活的麻风分枝杆菌能定期从真皮中清除,这一清除率与每日一次100毫克米诺环素治疗所达到的清除率相似。由于本研究中观察到的副作用比之前每日100毫克时更多,我们建议在应用米诺环素时,麻风患者应每日服用100毫克。